News in Brief

Published: 1-Mar-2003


  • Bristol-Myers Squibb has agreed to pay US$670m (€626m) to settle numerous lawsuits after it was accused of using illegal tactics to keep lower-priced versions of its medicines, cancer-fighting Taxol and the anti-anxiety drug BuSpar, out of the market for many months. Both drugs are now available as generic medicines.

  • The EU has initiated formal talks ; the first stage of disputes proceedings at the World Trade Organisation ; over import restrictions imposed by the Indian government on a range or products including penicillin, its salts, and derivatives, rifampicin, streptomycins or their derivatives, and first aid boxes or kits.

  • The European Agency for the Evaluation of Medicinal Products (EMEA) has announced that the EU marketing authorisation for hepatitis B treatment Hepacare has been withdrawn by the European Commission. The decision followed manufacturer Celltech Pharmaceuticals' commercial decision to abandon plans to sell the medicine. Alternative vaccines are available in Europe.

  • An EU-funded research project has identified four strains of lactobacilli that could help treat intestinal inflammations and infections. The aim of the Deprohealth scheme, which has received €1.4m ($1.5m) in Brussels money; is to develop oral probiotic bacteria vaccines to counter conditions such as rotavirus, which causes infant diarrhoea, and Crohn's disease. Participating researchers from France, Italy, Belgium, Spain, the UK and Australia have had to identify strains that not only prevented inflammation, but also could withstand human digestive acids.

  • A US federal judge has ruled that an approval letter with a delayed effective date given by the FDA should be considered merely a tentative approval and does not give a manufacturer the legal right to begin marketing a medicine. The judge was ruling against Barr Laboratories' bid to market a generic version of tamoxifen tablets, which the company had expected to release last August. He quashed a bid by Barr to overturn FDA restrictions on selling a product ahead of its release. The FDA had stressed that Barr should wait until the original patent currently held by AstraZeneca had expired.
    See more

    • You may also like

    Finance

    Shilpa Medicare opens flow chemistry manufacturing centre

    Read more
    The flow chemistry centre of excellence includes more than 100 R&D and manufacturing scientists

    Trending Articles

    1. Sheffield University’s Energy Innovation Centre advances sustainable aviation Precision Anton Paar instruments support cutting-edge SAF research
    2. Touchlight named most innovative new manufacturing facility at ISPE 2025 Facility of the Year Awards The company’s restored Victorian waterworks site in Hampton, London, has been recognised for transforming DNA manufacturing with its enzymatic, cell-free dbDNA platform
    3. Amphista Therapeutics nominates first clinical candidate AMX-883, a novel Targeted Glue degrader for acute myeloid leukaemia AMX-883, an orally available BRD9 degrader developed using Amphista’s Eclipsys platform, shows potent preclinical efficacy and a distinct DCAF16-based mechanism of action, paving the way for first-in-human trials in 2026
    4. Aseptic spray drying: Transforming biotherapeutics for a new era With interest in aseptic spray drying on the rise in the pharmaceutical industry, Dr Kevin Robinson spoke to GEA’s David Costes about how the company is combining process, engineering and technological expertise with market insights to provide a safe, reliable and high-performance technology for advanced biotherapeutic powder applications
    5. ACG to invest $200m in US hard-shell capsule manufacturing ACG will build its first US capsule manufacturing facility in Atlanta, Georgia, with dedicated gelatine and HPMC lines, creating more than 200 jobs and expanding its North American presence ahead of operations starting in early 2027

    You may also like

    Finance

    Shilpa Medicare opens flow chemistry manufacturing centre

    The flow chemistry centre of excellence includes more than 100 R&D and manufacturing scientists
    Manufacturing

    Frontline innovation: dispatches from the show floor at CPHI Frankfurt (part III)

    The third instalment from the CPHI Frankfurt show floor explores practical approaches and fresh perspectives on scale-up, tech transfer, and manufacturing innovation across the pharmaceutical sector
    Research & Development

    Immunology CRO reports shift to autoimmunity projects

    RoukenBio reports a sharp rise in autoimmunity drug development projects and an almost 50% decrease in immuno-oncology (I-O) studies, showcasing the shift in drug development trends
    Research & Development

    Merck partners with Promega to advance 3D cell drug discovery technologies

    Partnership combines Merck’s chemistry and organoid expertise with Promega’s assay technologies
    Manufacturing

    OPTIMA machinery USA Corporation marks 40 years of growth and innovation in the US

    OPTIMA machinery USA Corporation, a subsidiary of the German-based OPTIMA Packaging Group, is celebrating 40 years of successful operations in the United States
    Manufacturing

    Streamlining bioconjugation for next-generation ADC development

    Abzena’s proprietary ThioBridge™ technology delivers precision, scalability, and enhanced stability for antibody-drug conjugates
    Regulatory

    TurboFil offers industry-leading glove testing systems

    Partnership with RAVONA delivers precision and compliance in aseptic environments
    Subscribe now